Monday, June 11, 2018 10:16:50 AM
But for now, TLD-1433’s contribution to our revenue/EBITDA forecasts is solely driven by our royalty revenue projections in BCG-refractory NMIBC only.
(The company has already began work with brain and lung cancers as well as others.)
Bladder cancer-targeted PDT TLD-1433 is a major value driver in our model
http://67.212.93.22/research/content/20170905TLT%20final.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141398929
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM